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A B S T R A C T
Circulating tumor cells (CTCs) in the bloodstream are considered good indicators of the presence of a primary
tumor or even metastases. CTC capture has great importance in early detection of cancer, especially in
identifying novel therapeutic routes for cancer patients by ﬁnding personalized druggable targets for the
pharmaceutical industry. Recent developments in microﬂuidics and nanotechnology improved the ca-
pabilities of CTC detection and capture, including purity, selectivity and throughput. This article covers
the recent technological improvements in microﬂuidics-based CTC-capture methods utilizing the phys-
ical and biochemical properties of CTCs. We critically review the most promising hydrodynamic,
dielectrophoretic and magnetic force-based microﬂuidic CTC-capture devices.
© 2014 Elsevier B.V. All rights reserved.
Contents
1. Introduction ............................................................................................................................................................................................................................................................. 1
2. The hydrodynamic approach to rare-cell capture ...................................................................................................................................................................................... 2
3. Aﬃnity-based methods ........................................................................................................................................................................................................................................ 4
4. Dielectrophoretic capture ................................................................................................................................................................................................................................... 4
5. Magnetic trapping ................................................................................................................................................................................................................................................. 5
6. Conclusions and future prospects .................................................................................................................................................................................................................... 6
Acknowledgment ................................................................................................................................................................................................................................................... 7
References ................................................................................................................................................................................................................................................................ 7
1. Introduction
Tumor cells can shed into the bloodstream at a very early stage
of primary tumor growth and these so called circulating tumor cells
(CTCs) may give rise to metastases at distant parts of the body [1].
Detecting the presence of viable CTCs therefore provides a good in-
dicator for the presence of malignant transformations [2]. Isola-
tion and analysis of CTCs is important to improve understanding of
their nature, and their ability to initiate metastases, and for effec-
tive development of next-generation cancer therapeutics [3–5].
Primary tumors are usually detected at the stage of clinical symp-
toms by the non-invasive means of imaging techniques, such as tra-
ditional radiography (X-ray), magnetic resonance imaging (MRI),
computed tomography (CT), and ultrasound, or with invasive biopsy
collection. For example, cells shed from a primary tumor can ac-
cumulate in the bone marrow (BM) [6], necessitating invasive BM
biopsy to see their presence and possibly to monitor the effect of a
therapy. CTC-detection technologies can help substitute an inva-
sive biopsy for a simple blood draw, also referred to as liquid biopsy
[7–9].
At present, CTC-detection methods are not routinely used by cli-
nicians to make therapeutic decisions, mostly because of the lack
Abbreviations: BM, Bone marrow; CTC, Circulating tumor cell; DEP,
Dielectrophoresis; EGFR, Epithelial growth factor receptor; EpCAM, Epithelial cell
adhesion molecule; HeLa, Cervical cancer cell line; HER, Human epidermal growth
factor receptor; LNCaP, Androgen-sensitive human-prostate adenocarcinoma cell;
mAb, Monoclonal antibody; MCF-7, Michigan Cancer Foundation-7 breast-cancer cell
line; MDA-MB-231, Breast-cancer cell line; NSCLC, Non-small cell lung cancer; OEC-
M1, Human oral squamous cancer cell line; PBS, Phosphate buffered saline; PC-3,
Human prostate-cancer cell line; SCLC, Small-cell lung cancer; SKOV-3, Ovarian cancer
cell line; SW-620, Colon adenocarcinoma cell line.
* Corresponding author.
E-mail address: a.guttman@neu.edu (A. Guttman).
http://dx.doi.org/10.1016/j.trac.2014.02.017
0165-9936/© 2014 Elsevier B.V. All rights reserved.
Trends in Analytical Chemistry ■■ (2014) ■■–■■
ARTICLE IN PRESS
Please cite this article in press as: Laszlo Hajba, Andras Guttman, Circulating tumor-cell detection and capture using microfluidic devices, Trends in Analytical Chem-
istry (2014), doi: 10.1016/j.trac.2014.02.017
Contents lists available at ScienceDirect
Trends in Analytical Chemistry
journal homepage: www.elsevier.com/ locate / t rac
Q2
Q1
1
2
3
4
5
6
7
8
9
10
112
1314
1516
1718192021
2223
2425
267
289
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
of randomized data showing that therapies based on the CTC
numbers show improvement in prognosis [7]. The analytical valid-
ity of CTC-detection systems is crucial for their clinical accep-
tance, as emphasized in the guidelines recently published by the
US Food and Drug Administration (FDA) [10]. As of today, the only
FDA-approved CTC-detection method is the CellSearch System [11],
which is based on immunomagnetic detection of EpCAM positive
cells.
The most challenging part of effective CTC analysis is the cell-
capture design because of the extremely low abundance or rare-
event nature of these cells. For example, it is of great clinical
importance to enumerate quantitatively 0–10 CTCs per mL in whole
blood that also contains >109 erythrocytes and >106 leukocytes [12].
For sampling rare events in a large cell population, the following
should be considered:
(1) throughput, i.e. the number of cell identiﬁcation or sorting
steps per unit time;
(2) recovery, in the sense of the number of target cells collect-
ed from the input sample; and,
(3) purity, which depends on the number of “interfering” cells
excluded from the analysis [13].
Microﬂuidic systemswith small sample-volume requirement, fast
processing times, multiplexing capabilities and large surface area-
to-volume ratios offer an option for in-vitro cell sorting, detection
and single-cell analysis [14]. Based on these advantages, various
microﬂuidic platforms have been developed for rare-cell capture,
including CTCs [15]. Recent progress in microbiotechnology and
nanobiotechnology can also aid the development of more ad-
vanced CTC-detecting microﬂuidic devices [16].
Molecular proﬁling of CTCs can provide valuable information
about genetic mutations and can identify therapeutic targets for per-
sonalized treatment [17–19]. For example, in primary breast cancer,
human epidermal growth factor receptor-2 (HER2) is an impor-
tant treatment target, so presence of HER2-positive CTCs could be
a good indication for anti-HER2 treatments. Even in case of a HER2-
negative primary tumor veriﬁed by tissue biopsy, it might be rea-
sonable to use anti-HER2 treatment if HER2-positive CTCs are found.
Independent of the HER2 status of the primary tumor, the number
of HER2-positive CTCs usually correlates with decreased disease-
free survival and decreased overall survival [20]. Large prospec-
tive clinical trials have already been running to prove the eﬃciency
of anti-HER2 therapy based on the presence of HER2-positive CTCs
[21]. Another therapeutic target is the epithelial growth factor re-
ceptor (EGFR) in non-small cell lung cancer (NSCLC) patients.
Maheswaran et al. identiﬁed a mutation in EGFR by genotyping of
CTCs that cause drug resistance in NSCLC patients against EGFR-
inhibitor drugs [22]. Monitoring the tumor genotypes during lung-
cancer patient treatment, CTCs may provide information about
possible acquired resistance against EGFR-inhibitor drugs, so as to
help clinicians in therapeutic decision making.
In this article, we review the new advances and the state of the
art of the most commonly used CTC-capture methods for down-
stream analysis utilizing hydrodynamic, dielectrophoretic andmag-
netic forces to provide an adequate number of these important
marker cells for use in biomedical and clinical applications and de-
velopment of next-generation therapeutics.
2. The hydrodynamic approach to rare-cell capture
Hydrodynamic cell-capture methods in microﬂuidic settings
greatly depend on the interaction between the species of interest
and the microﬂuidic channel walls, and the sample-ﬂuid matrix. In
this section, we discuss label-free hydrodynamic capture methods
that are based on size, shape and cell deformability. The cell-wall
interaction can be further divided into continuous wall (channels)
and discrete wall (obstacles) [23]. In a continuous wall, the
microﬂuidic channel has a ﬂat surface and the ﬂow fractionation of
cells is controlled by pressure [24] or tuned by electroosmotic ﬂow
[25]. In the discretewall, the obstacles are usually posts and/or ridges.
Through a periodic array of µm-scale posts, with each row of posts
shifted horizontally with respect to the previous row, cells above
a critical size cannot be carried by the net vertical ﬂow but are lat-
erally displaced at each row. This lateral displacement is also af-
fected by the deformability of the cells. The critical size can be
calculated from the geometrical parameters of the posts (i.e. diam-
eter, gap between posts, and row shift) [26].
Based on the dominant forces, hydrodynamic separation can be
further classiﬁed into laminar-based, inertia-based and biomimetics-
based ﬂows [23].
In laminar-ﬂow-basedmicroﬂuidics where only the viscous force
is dominant (Re < 1), a cell follows a path that goes through its center
of mass. With carefully-designed ﬂow in a pinched segment of the
microchannel, the cells can be positioned in such away that the cells
of different sizes follow different paths and are consequently sepa-
rated by size [27]. At higher Reynolds number (1 < Re < 100), the in-
ertial force becomes the dominant separation force [28].
Biomimetics-based microﬂuidic devices have biologically in-
spired structural designs that can mimic physiological processes or
use biological principles (e.g. blood ﬂow inmicrocirculation). A good
example is amicroﬂuidic device thatwas developed to separate blood
cells using biomimetics [29]. The microchannels were designed so
that they mimicked microcirculation and enhanced the lateral mi-
gration of leukocytes. The average diameter of leukocytes is in the
range 10–12 μm [29] and the diameter of erythrocytes is 6.2–8.2
μm [30]. The red blood cells (erythrocytes) were concentrated in
the center of the microchannel, while the white blood cells (leu-
kocytes) laterally migrated to near the microchannel walls. The
biomimetics-based microﬂuidic device can achieve a 34-fold en-
richment of the leukocyte-to-erythrocyte ratio [29].
Microﬁltration is another useful technique for size-based rare-
cell trapping. Membrane microﬁlters are designed with well-
deﬁned pores to restrict passage for cells above a critical size. Similar
to other types of ﬁltration methods, any particulates commensu-
rable with the pore size can cause clogging. The usual size of a CTC
is >8 μm,which is greater than 90–95% of the largest blood-cell pop-
ulation, erythrocytes (red blood cells) [31,32]. Zheng et al. [33]. de-
signed amembranemicroﬁlter with 11-μmcircular pores and tested
it with a prostate-cancer cell line (LNCaP) diluted in human-blood
samples from healthy donors. With the average size of LNCaP cells
of 17 ± 1.5 μm, the recovery rate of membrane ﬁltration was
87.3 ± 7.0%. An improved 3D microﬁltration approach was pre-
sented by the same authors with the goals of minimizing the stress
on the cell membrane and sustaining cell viability with the same
recovery rate [34].
Microcavity arrays represent another special technique for size-
based capture of CTCs, as shown in Fig. 1. The microcavity-based
microﬂuidic device was tested with peripheral blood from healthy
donors spikedwithMCF-7 and SW-620 tumor cells. Microcavity sizes
were varied in the range 8–11 μm. The recovery rates for MCF-7 cells
(diameter 22.5 μm) remained almost constant with different
microcavity sizes at a level >90%. For the smaller tumor cells of SW-
620 (diameter 11.6 μm), the maximum recovery rate of 88% was ob-
tained using the average microcavity diameter of 9.1 μm [35]. A
rectangular type of microcavity array was also developed for effec-
tive capture of SCLC cells using microcavities with 5–9 μm width
and 30 μm length [36]. For SCLC cells, the recovery rate was ~80%.
Hydrodynamic lifting was recently developed by Geislinger et al.
for blood-cell separation [37]. The principle of the method was the
utilization of non-inertial hydrodynamic cell-wall interaction [i.e.
at very low Reynolds numbers (Re < 1), no inertial effects occur and
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the hydrodynamic lift (as a purely viscous effect) can provide ad-
equate cell separation] [38]. As shown in Fig. 2, the cells in the sample
ﬂow enter through a smaller inlet channel to the chamber where
the sample ﬂow is hydrodynamically focused by a perpendicular
sheath ﬂow. The square cross-section of the sheath ﬂow and sample
inlets were 110 μm × 110 μm and 110 μm × 30 μm (y- and z- direc-
tions), respectively. The main parameters that inﬂuenced the lateral
lift velocity were cell size and deformability. The cell radius con-
tributed cubically and cell deformability linearly to the lift veloci-
ty, respectively. This lab-on-a-chip system design could also separate
CTCs from blood samples.
The selectivity of hydrodynamic lifting-based cell sorting was
further enhanced by the application of spiral geometry. In this case,
the dominant inertial force and a secondary rotational ﬂow-ﬁeld per-
pendicular to the original ﬂow direction (Dean ﬂow) cause the
smaller particles to migrate in the direction of the outer half of the
channel and the bigger particles migrate towards the inner channel
wall [39,40]. This technique, referred to as Dean ﬂow ﬁeld fraction-
ation, can be applied to separate CTCs from blood cells with high
selectivity, based on their size differences [41]. Using double spiral
geometry (Fig. 3), the separation eﬃciency at the inner outlet of the
microchannel was found to be 98.72% for a binary test mixture of
5-μmand 15-μmdiameter polystyrene particles [42]. After the prom-
ising test results, experiments were conducted with 20× diluted
human blood drawn from healthy volunteers and spiked with HeLa
cells (tumor-to-blood cell ratio 8 × 10−7). At 60 mL/h ﬂow rate, the
separation eﬃciency for HeLa cells was 90.546 ± 3.41%with through-
put of 2.5 × 108 cells/min. Please note that the separation eﬃcien-
cy was deﬁned as the ratio of the number of one cell type collected
at the desired outlet (the inner outlet for HeLa cells or the middle
outlet for blood cells) to the total number of this kind of cell at all
outlets.
Fig. 1. Size-selective microcavity array-based CTC-recovery device (a) CTC detection. (b) Photograph of the size-selective microcavity array. (c) Photograph of the CTC-
recovery device equipped with the array. (d) Scanning electron microscope (SEM) image of MCF-7 cells trapped by the microcavity array. The microcavities were 9 μm in
size, with a 60 μm pitch. (© American Chemical Society [35]).
Fig. 2. Hydrodynamic lifting-based microﬂuidic device. Large arrows indicate the ﬂuid ﬂows. Cells separate in the z direction of the microchannel. (© American Institute of
Physics [37]).
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3. Aﬃnity-based methods
Although recent developments in the ﬁeld considerably in-
creased the separation eﬃciency of hydrodynamic label-free
methods, the maximum capture yield was still only around 90%. To
improve capture eﬃciency, special microposts were formed by pho-
tolithography in the channels of microﬂuidic devices and coatedwith
CTC-speciﬁc antibodies, such as anti-EpCAM [43]. The two essen-
tial parameters that determined the eﬃciency of cell capture in an
aﬃnity-coated microﬂuidic device were:
(1) ﬂow velocity, because it inﬂuenced the duration of cell–
micropost contact; and,
(2) low shear force to ensure maximum cell–micropost attach-
ment, which depends on the micropost distribution in the
microchannel [44].
A geometrically-enhanced aﬃnity-based microﬂuidic device re-
portedly captured 97 ± 3% of spiked LNCaP cells from PBS [45]. The
local topographical interaction can be enhanced by 3D
nanostructured cell-capture substrates. Densely-packed nanopillars
were prepared with diameters of 100–200 nm using wet chemical
etching, followed by coating with the relevant antibody (anti-
EpCAM). Cell-capture experiments were performed by employing
different nanopillar lengths in the range 4–20 μm. It was reported
that the capture yield for EpCAM-positive cells increased with
nanopillar length [46]. Optimal capture yield was attained when the
nanopillar lengths were comparable with the cell-protrusion lengths
of the CTCs [47].
To enhance antibody–CTC interaction, a special hydrogel was de-
veloped. A degradable alginate biopolymer coating enabled gentle,
eﬃcient release of antibody-captured cells from the microﬂuidic
device. The bottom of the microﬂuidic channel was coated with the
antibody (anti-EpCAM)-functionalized alginate biopolymer. PC-3 cells
were spiked into whole blood from a healthy donor and captured
in the microﬂuidic device. After the capture, alginate lyase was
pushed through the microﬂuidic channel, degrading the hydrogel
(alginate biopolymer) and releasing the captured cells [48]. The ad-
vantage of this approach was that this hydrogel coating mini-
mized non-speciﬁc interactions and enabled highly eﬃcient release
of the isolated cells (99% ± 1%) following hydrogel dissolutionwithout
any effect on cell viability.
A good example of the combination of hydrodynamic and aﬃnity-
based cell capture was published by Stott et al. [49]. Their
herringbone-chip design enabled passive mixing of blood cells
through the generation of microvortices that signiﬁcantly
increased the number of interactions between target CTCs and the
antibody-coated chip surface. The herringbone chip was tested with
the PC-3 prostate cancer cell line. The whole blood from healthy
donorswas spikedwith PC-3 cells at a concentration of 500 cellsmL.
The capture eﬃciency was 91.8 ± 5.2% for the spiked PC-3 cells.
4. Dielectrophoretic capture
Dielectrophoresis (DEP) is a phenomenon bywhich a subject (e.g.
cell) is forced to move by the application of divergent electric ﬁeld
gradients due to polarization forces. DEP forces depend on differ-
ent factors, such as cell-membrane and cytoplasm-charge proper-
ties, and size. The electric ﬁeld induces charges within the cell,
forming dipoles. If the cell is more polarizable than the suspend-
ing medium, it is attracted towards the regions of higher electric
ﬁelds, and the motion is called positive DEP. Conversely, if the cell
is less polarizable than the suspending medium, it is repelled from
the regions of higher electric ﬁeld, and the motion is called nega-
tive DEP [50,51].
DEP techniques can also be distinguished bymicroelectrode type.
Metallic microelectrodes with various geometries can be used {e.g.
interdigitated [52], castellated [53], oblique [54], spiral [55], circu-
lar [56], ring shape [57], and wedge shape [58], that are patterned
on a microﬂuidic wafer using conventional lithography
techniques}.
Contactless DEP (cDEP) was developed for cell manipulation and
sorting [59] so that the conventional metallic microelectrodes were
replaced by ﬂuidic electrode channels, ﬁlled with high-conductivity
ﬂuids. Application of this technique, eliminated problems (e.g. bubble
formation and electrode-sample contamination) [60] and de-
creased fabrication costs.
Davis and co-workers recently developed a high-throughput
continuous-ﬂow DEP microﬂuidic device, named ApoStream [61],
where an AC electric ﬁeld was applied to the sample within opti-
mized ﬂow-path regions. The ﬂoor of the ﬂow chamber comprised
a ﬂexible polyimide ﬁlm sheet with electroplated copper and gold
electrodes. An acrylic sheet formed the ceiling and a gasket the side
walls. The sample was injected through a port located at the ﬂoor
of the ﬂow chamber at the same upstream end as the elution buffer.
Cancer cells were collected through another port located down-
stream from the sample inlet port (Fig. 4).
With the setting shown in Fig. 4, the average recovery of SKOV-3
andMDA-MB-231 cancer cells, spiked into 12 × 106 peripheral blood
mononuclear cells obtained from normal human-donor blood, was
75.4% ± 3.1% (number of samples was 12) and 71.2% ± 1.6% (number
of samples was 6), respectively. These percentage values were much
Fig. 3. (a) Microﬂuidic cell sorter containing a six-loop double-spiral microchannel. (b) Picture of the assembled cell sorter. (© American Institute of Physics [42]).
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higher than in other reports using the DEP method [52] and the vi-
ability of the captured MDA-MB-231cancer cells was greater than
97.1%.
Lee and co-workers developed a high-purity CTC-isolation tech-
nique based on optically-induced DEP (ODEP) [62], which fea-
tured a sandwich structure with top and bottom layers made of
indium-tin-oxide (ITO) glass, and the bottom layer had a photo-
conductive coating (hydrogenated amorphous silicon). Between these
layers, therewas a liquid layer containing the sample. An alternating-
current (AC) voltage was ﬁrst applied in the ODEP system to produce
a uniform electric ﬁeld. After optical illumination, electron-hole pairs
were generated in the photoconductive layer, causing signiﬁcant in-
crease in the conductivity of the bottom layer. This phenomenon
allowed the applied voltage to drop across the liquid layer, produc-
ing a locally non-uniform electric ﬁeld at the illuminated regions
[63]. With this method, the recovery rate was 76–83% for PC-3 cells,
and 61–68% for OEC-M1 cells with ~95% viability [62]. The viabil-
ity of the captured CTCs also depended on the applied voltage and
the frequency of the DEP ﬁeld, so DEP operation conditions needed
to be carefully optimized to avoid collection of non-viable cells
[64,65]. A low-intensity, intermediate-frequency alternating elec-
tric ﬁeld (100–300 kHz) might have an inhibitory effect on the
growth rate of a variety of human-tumor cell lines [66].
5. Magnetic trapping
Magnetic-trapping techniques utilize magnetic particles with
magnetic-ﬁeld manipulation. Magnetic particles are typically sized
in the range of several nanometers to a couple of micrometers and
they have a magnetic core and a non-magnetic coating that can be
chemically modiﬁed [15,67]. In microﬂuidic systems, both perma-
nent magnets and/or electromagnets can be used. Passive magnet-
ic [68] elements or electromagnets [69,70] are usually assembled
in the wall of the microchannels to trap the magnetic particles at
the surface of the microchannel.
Effective capture of MCF-7 breast-cancer cells in a microﬂuidic
chip with self-assembled protein-coated magnetic beads was dem-
onstrated by Sivagnanam et al. [71]. The beads were patterned in
situ inside a sealed microﬂuidic channel by magnetic-ﬁeld-assisted
electrostatic self-assembly and grafted by 5D10 monoclonal anti-
bodies. The capture eﬃciency of the system for MCF-7 cells was
85 ± 10%.
Superparamagnetic beads were also utilized for magnetic cell
capture. In the so-called Ephesia system, these beads self-assembled
in a microﬂuidic channel into an array of magnetic traps prepared
by microcontact printing. This approach combined the advantages
of microﬂuidic cell sorting, notably the application of a well-
controlled, ﬂow-activated interaction between cells and beads, and
immunomagnetic sorting. The superparamagnetic beads were an-
tibody (anti-EpCAM)-coated for CTC capture [72]. Under a moder-
ate external magnetic ﬁeld, dipole-dipole interactions between the
magnetic bead particles formed chains aligned along the electric ﬁeld
direction forming nanopillar-like structures [73]. The principle of
this technology is depicted in Fig. 5. Cell-capture yield reached 94%
with this approach.
Another interesting approach is the utilization of magnetophoretic
mobility [i.e. the motion of particles in a viscous medium induced
by a magnetic ﬁeld on a particle or cell of magnetic or magnetiz-
able material (e.g. magnetically-labeled cells)] [74]. Murthy and co-
workers developed a continuous-ﬂow,magnetophoretic, microﬂuidic,
Fig. 4. A continuous ﬂow dielectrophoresis (DEP) microﬂuidic cell-sorting device. (© American Institute of Physics [61]).
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rare-cell-capture devicewith the principle of applying a laminar ﬂow
in the y-direction and a magnetic ﬁeld in the x-direction, so the
magnetically-tagged cells moved from the outside sample streams
to the center collection stream (Fig. 6) [75]. To test the capability
of the set-up, 50 MCF-7 cells were spiked into 1-mL blood from
healthy volunteers. The blood samples were thenmixed with Dynal
MyOne anti-EpCAM-functionalizedmagnetic beads and applied. The
capture eﬃciency was greater than 85% with purity over 90% [75].
An interesting approach with a negative CTC-enrichment tech-
nique was also developed utilizing the combination of viscous ﬂow
andmagnetic force to facilitate the recovery of unlabeled cells (CTCs)
from whole-blood samples obtained from cancer patients [76,77].
The method was based on removal of erythrocytes by lysis fol-
lowed by the magnetic separation of immunomagnetically-labeled
(with CD45 antibody) leukocytes. After themagnetic separation, the
remaining cells were considered mostly CTCs.
6. Conclusions and future prospects
Recent advances in nanotechnology andmicroﬂuidics havemade
possible the design and the implementation of highly-reliable CTC-
capture platforms with excellent yield and selectivity for the most
common types of cancer cell. Capture systems with high through-
put, rapid processing times and minimal false-positive rates are
highly desirable in themedical and diagnostic ﬁelds to monitor pro-
gress during cancer therapy and, more importantly, for early cancer
detection. Molecular proﬁling of CTCs can also help to identify new
targets and so can aid development of novel therapeutic agents. For
wider acceptance, the capabilities of CTC targeting microﬂuidic de-
tection and capture devices should be demonstrated on a large
variety of cancer types. In addition, for proper regulatory approv-
als, the analytical validity of the CTC assay should be rigorously tested
based on Clinical Laboratory Improvement Amendments (CLIA) or
Good Laboratory Practice (GLP) standards.
We expect that, in the near future, once such microﬂuidic CTC
detection and capture devices are approved by the regulatory agen-
cies, they will quickly ﬁnd their way for routine use in personal-
ized therapeutics for cancer patients.
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